Masimo (BSP:M2AS34) Moat Score: 6/10 (As of Jun. 26, 2026)


BSP:M2AS34 Masimo Corp BSP:M2AS34
55 GF Score
Price R$39.00
GF Value R$36.87
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Masimo Moat Score?

Masimo BSP:M2AS34 +27.16% 55 Moat Score is 6 as of Jun. 26, 2026. GuruFocus rates BSP:M2AS34 with a GF Score™ of 55/100 and a GF Value™ of R$36.87 (Fairly Valued). The stock has 9 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Masimo ranks better than 95.74% on this metric.

Masimo has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Masimo has Narrow Moat: Masimo Corp has a strong narrow moat due to its valuable patents and consistent innovation in medical technology. However, it faces competitive pressures that prevent a wide moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Masimo might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Masimo  (BSP:M2AS34) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Masimo Moat Score Related Terms

BSP:M2AS34 vs BRKR, PODD, BIO: Moat Score Comparison

For the Medical Devices subindustry, Masimo's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Masimo Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Masimo's Moat Score distribution charts can be found below:

* The bar in red indicates where Masimo's Moat Score falls into.


BSP:M2AS34
55GF Score
Masimo Corp BSP:M2AS34
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Masimo (BSP:M2AS34) has a Moat Score of 6 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Masimo ranks #36 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is Masimo's Moat Score too high?
Masimo's current Moat Score is 6. Based on the distribution chart, Masimo ranks #36 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Masimo has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Masimo's Moat Score compare to BRKR and PODD?
According to the Medical Devices & Instruments industry distribution chart, Masimo ranks #36 out of 846 companies for Moat Score. This places Masimo in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Masimo's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Masimo stock overvalued right now?
Based on GuruFocus' analysis, Masimo (BSP:M2AS34) is currently considered Fairly Valued. The stock's GF Value™ is R$36.87, compared to a current price of R$39.00 — trading 5.8% above its estimated fair value. The current Moat Score is 6. Masimo's overall GF Score™ is 55/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Masimo (BSP:M2AS34), the current Moat Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Masimo (BSP:M2AS34) Overvalued in 2026?

Based on GuruFocus' analysis, Masimo stock appears to be overvalued. The current stock price of R$39.00 is trading 5.8% above its estimated GF Value™ of R$36.87. GuruFocus considers Masimo to be Fairly Valued.

Key valuation signals for BSP:M2AS34:

  • Moat Score: 6
  • GF Value™: R$36.87 vs. price of R$39.00 (5.8% above fair value)
  • GF Score™: 55/100 with 9 warning signs

No single metric tells the full story. See the BSP:M2AS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Masimo Business Description

Address 52 Discovery, Irvine, CA, USA, 92618
Masimo Corp is a medical technology company. The company oepates in single segment namely Healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and others.
55GF Score

Get the complete analysis for BSP:M2AS34

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$39.00
Price
R$36.87
GF Value